PharmacovigilanceOfficial

Infarmed launches monthly 'Deep Dive' publication, opening with migraine medicines

🇵🇹 INFARMED · Fri 23 Oct 2026

Portugal's medicines authority has introduced a monthly series analysing therapeutic areas and medicines policy measures, starting with treatments used to prevent and treat migraine.

Infarmed, the Portuguese medicines authority, has launched Deep Dive, a new monthly publication on medicines and other health products. It was announced on 23 October 2026.

According to the agency, each edition will look in greater depth at different therapeutic areas and at policy measures affecting medicines and health products. Infarmed says it is aiming for a clear and objective approach that improves understanding of how these products are used in Portugal.

The first edition covers migraine. It focuses on the medicines used to treat and to prevent the condition, and on their role in improving quality of life for people living with it. A summary infographic is available as an attachment to the announcement.

The announcement does not describe the data sources behind the series, nor does it say whether pharmacovigilance or safety information will feature. It sets out no regulatory requirements. Queries can be sent to the contact address given by Infarmed, dipe@infarmed.pt.

What it means for your team

  • Market-access and HEOR teams working in Portugal may find the series a useful reference for national medicine-use trends and policy measures, although the data sources have not been specified.
  • Teams with migraine products could review the first edition and its infographic to see how Infarmed frames treatment and prevention.
  • No new obligations or deadlines are attached to the publication; regulatory and PV teams need take no compliance action.
  • Future monthly topics have not been announced, so the usefulness for other therapeutic areas is not yet clear.

Official source: INFARMED ↗

Article written by VigiEye from the official source (INFARMED). AI-assisted; check the source before acting.

More Pharmacovigilance All →